4-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfamide ;Glyburide Related Compound A (25 mg) (5-chloro-2-methoxy-N-[2-(4-sulfamoylphenyl)ethyl]benzamide);4-[2-(2-Methoxy-5-chlorobenzene-1-carboxaMido)ethyl]benzenesulfonaMide;5-Chloro-N-(p-sulfaMoylphenethyl)-o-anisaMide;GlibenclaMide (Glyburide) IMpurity A;Glyburide Related CoMpound A;Glyburide Related Compound A (25 mg) (4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzenesulfonamide);Glyburide USP RC A
NLRP3i (16673-34-0) is an NLRP3 inflammasome inhibitor which likely acts via interfering with the formation of the NLRP3 inflammasome complex and which exhibits promising?in vivo?protective activities in mouse acute myocardial infarction models. It blocks ASC aggregation, blocks the release of IL-1β and the activation of caspase-1 in macrophages expressing constitutively active NLRP3 but does not directly inhibit caspase-1.1,2?Limits infarct size after myocardial ischemia-reperfusion as well as leukocyte infiltration in a peritonitis model in mice.2
